Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P05154

UPID:
IPSP_HUMAN

ALTERNATIVE NAMES:
Acrosomal serine protease inhibitor; Plasminogen activator inhibitor 3; Protein C inhibitor; Serpin A5

ALTERNATIVE UPACC:
P05154; Q07616; Q9UG30

BACKGROUND:
Plasma serine protease inhibitor, known by names such as Protein C inhibitor and Serpin A5, is a heparin-dependent serine protease inhibitor with crucial roles in body fluids and secretions. It regulates intravascular and extravascular proteolytic activities, affecting hemostasis, inflammation, sperm motility, and fertilization by inhibiting a range of serine proteases, including those involved in blood coagulation and seminal fluid dynamics.

THERAPEUTIC SIGNIFICANCE:
The therapeutic potential of Plasma serine protease inhibitor is significant. By elucidating its regulatory mechanisms on proteolytic activities related to coagulation, inflammation, and reproduction, novel therapeutic approaches could be developed for treating related pathologies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.